U.S. markets open in 1 hour 53 minutes

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
109.84+0.34 (+0.31%)
Al cierre: 04:00PM EST
110.85 +1.01 (+0.92%)
Antes de la apertura del mercado: 07:25AM EST

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo6,300

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Kevin Ronald SayerExec. Chairman, CEO & Pres2.39MN/D1958
Mr. Jereme M. SylvainExec. VP, CFO & Chief Accounting Officer783.16kN/D1980
Mr. Jacob Steven LeachExec. VP & COO915.93kN/D1978
Mr. Paul R. FlynnExec. VP of Global Revenue761.52kN/D1969
Mr. Girish NaganathanExec. VP of R&D and CTON/DN/DN/D
Mr. Sean ChristensenDirector of Corp. Affairs & Head of Investor RelationsN/DN/DN/D
Mr. Michael BrownExec. VP & Chief Legal OfficerN/DN/D1970
Mr. Matthew DolanExec. VP of Strategy, Corp. Devel. & Dexcom LabsN/DN/D1981
Ms. Sadie M. SternExec. VP & Chief HR OfficerN/DN/D1975
Mr. Andrew K. BaloExec. VP of Global Medical Affairs, Access & EvidenceN/DN/D1948
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de DexCom, Inc. a partir del 1 de febrero de 2023 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 10; Derechos del accionista: 6; Compensación: 6.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.